Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pagibaximab in very low birth weight neonates for S. epidermidis prevention
NCT00631878Phase 2Completed
- Sponsor
- Biosynexus Incorporated
- Start
- Nov 2001
- Primary completion
- May 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pagibaximab in Staphylococcus epidermidis infection, sponsored by Biosynexus Incorporated. Started Nov 2001; status: completed.
02
Drugs
pagibaximab
03
Conditions
Staphylococcus epidermidis infection
Beyond the preview
Go deeper on NCT00631878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00631878.